Login to Your Account

In The Clinic NEWS

With primary endpoint-missing phase IIb data in hand, Otonomy Inc. CEO David Webber said he is "more confident today" that OTO-104 for Meniere's disease is a viable product, and the company will be meeting with the FDA to talk about the planned phase III program.

Lpath Inc.'s stock plunged 79.5 percent on word of the lead compound's phase II blowup, but "there exists some true assets that can be built upon," spokeswoman Pam Lord told BioWorld Today, and the company is restructuring to conserve money.

Following extensive talks with the FDA and European regulators, Intercept Pharmaceuticals Inc. has nailed down plans for a rigorous pivotal phase III study testing obeticholic acid, its lead candidate, in about 2,500 patients with NASH.

More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: